A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). mAPMR is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone treatments designed to block male hormones (androgens).

Trial Details

NCT ID
NCT07906717
Phase
PHASE3
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • JNJ-101556143
  • Placebo
  • Best Supportive Care
Locations (sample)
  • El Paso, Texas, United States|31.75872,-106.48693
  • The Woodlands, Texas, United States|30.15799,-95.48938
  • Murray, Utah, United States|40.66689,-111.88799
  • Haifa, Israel|32.81303,34.99928

Key Eligibility Criteria

  • Have histologically confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tum…
  • Progressive metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level grea…
  • Participants should have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which t…
  • Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog \[agonist or antagonis…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →